Please check your internet connection and try again.
# Clobazam (Oral Formulation)
## Overview
Clobazam is a benzodiazepine derivative with anticonvulsant properties. It is used as adjunctive therapy for seizures associated with Lennox-Gastaut syndrome (LGS).
## Primary Indications
* Adjunctive therapy for seizures in patients 2 years of age and older with Lennox-Gastaut syndrome (LGS).
## Adult Dosing
* **Initiation:** Start at 5 mg twice daily.
* **Titration:** Increase dose every week based on clinical response and tolerability, not to exceed 20 mg twice daily.
* **Maintenance:** Typical maintenance doses range from 5-20 mg twice daily. Maximum recommended daily dose is 40 mg.
## Pediatric Dosing (2 years and older)
* **Initiation:** Start at 5 mg twice daily.
* **Titration:** Increase dose every week based on clinical response and tolerability. Dosing is weight-based:
* **2-10 years or <30 kg:** Not to exceed 10 mg twice daily.
* **>10 years or ≥30 kg:** Not to exceed 20 mg twice daily.
* **Maintenance:** Typical maintenance doses are weight-based:
* **2-10 years or <30 kg:** 5-10 mg twice daily.
* **>10 years or ≥30 kg:** 10-20 mg twice daily.
* Maximum recommended daily dose for all pediatric patients is 40 mg.
## Dose Adjustments
* **Hepatic Impairment:** Use with caution. No specific dose adjustments are established, but a lower starting dose and slower titration may be warranted.
* **Renal Impairment:** Use with caution. No specific dose adjustments are established.
## Contraindications
* Known hypersensitivity to clobazam or other benzodiazepines.
## Adverse Effects
Common adverse effects include somnolence, decreased appetite, aggression, irritability, constipation, vomiting, and ataxia. Serious adverse effects include severe skin reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis), withdrawal symptoms, and potential for respiratory depression, especially when used with other CNS depressants.
## Key Drug Interactions
* **CNS Depressants (e.g., alcohol, opioids, other benzodiazepines):** Increased risk of sedation, respiratory depression, and coma.
* **CYP2C19 Inhibitors (e.g., fluconazole, omeprazole):** May increase clobazam concentrations.
* **CYP2C19 Inducers (e.g., rifampin):** May decrease clobazam concentrations.
* **Strong CYP3A4 Inhibitors (e.g., ketoconazole, ritonavir):** May increase clobazam concentrations.
## Monitoring
* Monitor for efficacy (seizure frequency).
* Monitor for adverse effects, particularly somnolence, behavioral changes, and signs of severe skin reactions.
* Monitor for signs of withdrawal upon discontinuation.
## Clinical Pearls
* Clobazam should be used as adjunctive therapy and not as monotherapy for LGS.
* Withdrawal symptoms can occur upon abrupt discontinuation. Tapering the dose gradually is recommended.
* Patients and caregivers should be advised about the risk of serious skin reactions and instructed to discontinue the drug and seek immediate medical attention if rash or blistering occurs.
* Due to the risk of somnolence, patients should be cautioned about driving or operating heavy machinery until they know how clobazam affects them.
***
*This information is intended for healthcare professionals. Please consult the most current prescribing information and relevant guidelines for complete details. Always exercise clinical judgment.*
